AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2003, for Hemispherx Biopharma, Inc. The company is a biopharmaceutical firm focused on developing nucleic acid-based therapeutics, primarily Ampligen(R) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and HIV. In March 2003, the company acquired inventory and limited marketing rights for ALFERON N Injection (a treatment for genital warts) from Interferon Sciences, Inc. (ISI), marking a shift toward commercial product sales alongside clinical development.

Key Financial Metrics

Revenue Breakdown (Six Months 2003): Product sales of $79,000 (ALFERON N) and clinical treatment programs of $81,000. No license fee income was recognized in this period, compared to $563,000 in the prior year.

Debt and Liquidity: The company issued $5.426 million in 6% Senior Convertible Debentures in March 2003 and another $5.426 million in July 2003. Due to beneficial conversion features and warrants, the carrying value of the debt was reduced to zero, with approximately $2.0 million amortized as non-cash interest expense in the first six months of 2003.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues for the six months ended June 30, 2003, dropped to $160,000 from $747,000 in the prior year. This decrease is primarily due to the absence of a one-time $563,000 license fee recognized in 2002 from a European distribution agreement.
• Net Loss Increase: Net loss increased to $5.306 million (six months 2003) from $4.122 million (six months 2002). This increase is largely driven by $1.956 million in non-cash interest charges related to the new convertible debentures and $342,000 in expenses related to the new ALFERON N division.
• Operating Expense Reduction: Excluding non-cash interest and new division costs, operating losses decreased. Research and Development (R&D) expenses fell by $703,000 year-over-year due to the winding down of the Phase III ME/CFS clinical trial.
• Asset Acquisition: The balance sheet reflects $2.167 million in inventory (ALFERON N) and $1.068 million in deferred acquisition costs related to the ISI asset purchase, which were not present in the prior period.

Guidance, Outlook, and Risks

Outlook: Management projects a need for approximately $2.0 million in additional financing over the next 12 months to fund operations and debt service, assuming debenture holders do not convert remaining debt to equity. The company expects to complete the ME/CFS Phase III trial by Q1 2004 and file a New Drug Application (NDA) by Q2 2004.

Key Risks and Contingencies:

• Authorized Share Limitation: As of July 2003, only ~104,000 authorized shares remained unissued. The company's ability to raise capital or satisfy conversion rights is severely restricted unless stockholders approve an increase to 100 million shares at the September 2003 annual meeting.
• Share Price Guarantee: The company guaranteed the value of ~1.43 million shares issued to ISI and its creditors at $1.59 per share. If the stock price is below this threshold at termination dates (12-24 months post-issuance), the company may be obligated to repurchase shares, creating a potential liability of up to $2.275 million.
• ISI Facility Acquisition: $1.55 million of debenture proceeds is held back pending the acquisition of ISI's production facility. Failure to close this acquisition within 90 days of July 10, 2003, could trigger a technical default and require redemption of the debentures.
• Regulatory Approval: Ampligen(R) remains investigational. Commercialization depends on FDA approval, which is not guaranteed.

Investor Verification Checklist

• Capital Raise Status: Verify the outcome of the September 2003 shareholder vote to increase authorized shares from 50 million to 100 million.
• ISI Acquisition Timeline: Confirm whether the second agreement to acquire ISI's production facility was completed within the required 90-day window to release the $1.55 million held-back funds.
• Debt Conversion Activity: Monitor the rate at which debenture holders convert debt to equity, as this impacts cash flow requirements and dilution.
• Share Price vs. Guarantee: Track the stock price relative to the $1.59 guarantee floor to assess potential repurchase liabilities.
• ALFERON N Sales: Review subsequent quarterly reports for actual sales volume of ALFERON N to determine if it meets projections sufficient to offset operating losses.